After a series of late-stage failures in the clinic, Sanofi SA is falling back on its longstanding partner, Regeneron Inc., ...

Stryker Corp. chair and CEO Kevin Lobo expects AI to be a major force in healthcare. At the LSI Europe summit in Barcelona this week, he described AI as “an intelligent partner” that will help bring ...

Efforts to restore the pancreas’ insulin-producing capacity are moving beyond glucose control and toward regeneration. At the European Association for the Study of Diabetes (EASD) meeting, several ...

The final rule of the U.S. Centers for Medicare & Medicaid Services’ (CMS) GLOBE program, an effort by the Trump administration to bring drug prices in line with other countries, is expected to save ...

Atara Biotherapeutics Inc. and partner Pierre Fabre Pharmaceuticals Inc. lodged a third bid for U.S. FDA approval of tabelecleucel (tab-cel; Ebvallo), submitting additional clinical and manufacturing ...

A nixed $1.68 billion oncology deal from 2021 has left Foghorn Therapeutics Inc. facing a reprioritization and a 40% ...

Melbourne-based Paradigm Biopharmaceuticals Ltd. has entered voluntary administration after an interim analysis found its pivotal phase III trial of Zilosul (injectable pentosan polysulfate) in knee ...

Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib produced more than two-and-a-half times the complete ...

Even as analysts and investors scrutinized detailed phase III findings from its triple-G obesity candidate, retatrutide, Eli ...

Pharma companies are contributing proprietary data to feed a foundation AI model that will predict at the earliest stages of ...

At this year’s meeting of the American Society of Clinical Oncology in Chicago, Aprea Therapeutics Inc. made a splash with ...

Xeltis BV has begun commercialization of Axess, its vascular access conduit for hemodialysis in Germany and Iberia, and ...